Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

Targeting ABC transporters in PDAC - past, present, or future?

“…For patients with metastatic disease, it is used to slow the progression, with a median overall survival of 10 months [ 13 ]. Inherent or acquired chemoresistance is responsible for a poor prognosis and there is a lack of therapeutic options to overcome it [ 14 ]. In fact, the only current alternative in case of progression after GnP is the alternation with FOLFIRINOX or modified 5-FU-based regimens such as FOLFOX or FOLFIRI [ 6 ], provided that the health status of the patient allows such treatment adjustments.…”